Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms and signs is more effective than treatment guided by clinical symptoms and signs alone in patients with HF and left ventricular systolic dysfunction

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Bisoprolol; Candesartan; Captopril; Carvedilol; Diuretics; Enalapril; Eplerenone; Lisinopril; Metoprolol; Natriuretic Peptide, Brain; Ramipril; Spironolactone; Trandolapril; Valsartan

Criteria

Inclusion Criteria:

• Female/male, over 18 years with previously verified HF with left ventricular systolic dysfunction.

• New York Heart Association(NYHA) class II-IV,

• NTproBNP males>800 ng/L, females >1000 ng/L

Exclusion Criteria:

• Planned CV hospitalisation, stroke or acute myocardial infarction (MI) last 3 months,

• Mitral/aortic stenosis,

• Patients already receiving optimal HF treatment,

• Severe reduction of kidney function